Intravenous Iron Versus Placebo in the Management of Postoperative Functional Iron Deficiency Anemia in Patients Undergoing Cardiac Valvular Surgery: A Prospective, Single-Blinded, Randomized Controlled Trial

Objective To compare the efficacy of intravenous iron versus placebo to correct postoperative functional iron deficiency anemia in patients undergoing cardiac valvular surgery. Design A prospective, single-blinded, randomized controlled study. Setting National Center for Cardiovascular Diseases and a university hospital. Participants The study comprised 150 patients with postoperative functional iron deficiency anemia after cardiac valvular surgery. Interventions The patients were randomly assigned (1:1) to either the treatment (intravenous iron) group or the control (placebo) group. Measurements and Main Results The hemoglobin and ferritin concentrations and postoperative adverse events were collected and compared between the 2 groups. The hemoglobin concentration and the proportion of patients who had their anemia corrected or achieved hemoglobin increments of >20g/L in the intravenous iron group were significantly higher than that in the placebo group at postoperative day 14 (p = 0.023, p = 0.037, and p = 0.001), whereas there was no statistical difference at postoperative day 7. The ferritin concentration was substantially higher at postoperative day 7 and postoperative day 14 in the intravenous iron group compared with the placebo group (both p 24hours, postoperative hospital stay >10days, poor wound healing, and perivalvular leakage between the 2 groups. Conclusions Intravenous iron could significantly increase the hemoglobin level in patients with postoperative functional iron deficiency anemia at postoperative day 14. However, there is no difference in blood transfusion requirements or postoperative adverse outcomes between the 2 groups.